 Shares of CinCor Pharma Inc. CINC, 3.51 fell 41.6 in premarket trading on Monday after the company said its experimental hypertension drug failed to meet the primary endpoint in a Phase 2 clinical trial. CinCor said it still plans to meet with the Food and Drug Administration in January to discuss plans for its Phase 3 program for baxdrostat. 